Infusion pump maker Hospira (NYSE:HSP) restated its 2013 financial guidance after the FDA banned imports of certain of Hospira’s infusion pumps.
Hospira Inc.
BlackRock boosts medical device stakes
BlackRock Inc., 1 of the world’s largest hedge funds, boosted its stake in a clutch of medical device companies, with 1 exception.
FDA blocks Hospira Symbiq touchscreen-enabled infusion pump imports
Recall: Hospira infusion pump touchscreen issue gets Class I status from FDA
FDA warns infusion pump maker over violations at Costa Rica plant
Infusion pump maker Hospira (NYSE:HSP) received an FDA warning after the federal watchdog agency recorded manufacturing violations at the company’s Costa Rica manufacturing facility.
In September 2011 Hospira recalled certain Plum infusion pumps after receiving reports that the devices’ alarms were not functioning.
Smith & Nephew subsidiary names new chairman | Personnel Moves
Steve Nunes resigns from MAKO | Personnel Moves
Thoratec kills it in Q1, Wall Street shrugs | Earnings Roundup
Thoratec (NSDQ:THOR) started today up 7.2% as investors reacted to its stellar 1st-quarter numbers, but by the time the market closed THOR shares had fallen back to Earth to close at $34.46, down 0.1%.
The heart pump maker posted profits of $25.5 million, or 43¢ per diluted share, on sales of $126.8 million for the 3 months ended March 31.
Smith & Nephew adds Baroness Bottomley to board of directors | Personnel Moves
British orthopedic giant Smith & Nephew (NYSE:SNN) added former Parliament member and conservative politician Baroness Virginia Bottomley of Nettlestone to its board of directors.
Bottomley served in the U.K.’s House of Commons from 1984 to 2005, after which she was raised to "peerage," a term of ranking for British nobility.
Diabetes: Abbott lands FDA win for touch-screen glucose monitor | Regulatory Roundup
Moody’s estimates med-tech tax impact
The 2.3% tax on revenues slated to go into effect next year for medical device makers could top $650 million for the med-tech companies covered by Moody’s Investor Services, according to a report by the ratings agency.
The tax will help slow EBIDTA growth rates for the med-tech sector to between 1% and 4% over the next year to 18 months, according to Moody’s, with organic growth rates of between 2% and 3% during that period.
